AP3346A - Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same - Google Patents
Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the sameInfo
- Publication number
- AP3346A AP3346A AP2012006191A AP2012006191A AP3346A AP 3346 A AP3346 A AP 3346A AP 2012006191 A AP2012006191 A AP 2012006191A AP 2012006191 A AP2012006191 A AP 2012006191A AP 3346 A AP3346 A AP 3346A
- Authority
- AP
- ARIPO
- Prior art keywords
- same
- preparing
- pharmaceutical composition
- composition containing
- novel compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20090095363 | 2009-10-07 | ||
| PCT/KR2010/006760 WO2011043568A2 (en) | 2009-10-07 | 2010-10-04 | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2012006191A0 AP2012006191A0 (en) | 2012-04-30 |
| AP3346A true AP3346A (en) | 2015-07-31 |
Family
ID=43857261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2012006191A AP3346A (en) | 2009-10-07 | 2010-10-04 | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8729273B2 (es) |
| EP (1) | EP2467378B1 (es) |
| JP (1) | JP5702392B2 (es) |
| KR (1) | KR101751325B1 (es) |
| CN (1) | CN102574839B (es) |
| AP (1) | AP3346A (es) |
| AR (1) | AR078504A1 (es) |
| AU (1) | AU2010304091B2 (es) |
| BR (1) | BR112012007828B8 (es) |
| CA (1) | CA2774133C (es) |
| CL (1) | CL2012000738A1 (es) |
| CO (1) | CO6430501A2 (es) |
| EA (1) | EA021025B1 (es) |
| EC (1) | ECSP12011793A (es) |
| ES (1) | ES2599829T3 (es) |
| IL (1) | IL218669A (es) |
| MA (1) | MA33880B1 (es) |
| MX (1) | MX2012003782A (es) |
| MY (1) | MY162813A (es) |
| PE (1) | PE20121088A1 (es) |
| SG (1) | SG179186A1 (es) |
| TR (1) | TR201203989T1 (es) |
| TW (1) | TWI423962B (es) |
| UA (1) | UA110197C2 (es) |
| WO (1) | WO2011043568A2 (es) |
| ZA (1) | ZA201202544B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI548630B (zh) * | 2011-04-06 | 2016-09-11 | Lg生命科學有限公司 | 1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸結晶型及其製造方法 |
| US9981918B2 (en) * | 2011-08-30 | 2018-05-29 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| PT2980085T (pt) | 2013-03-29 | 2018-04-09 | Teijin Pharma Ltd | Compostos farmaceuticamente activos |
| KR20170026633A (ko) | 2014-07-17 | 2017-03-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | Hiv-관련 장애의 치료 방법 및 치료용 조성물 |
| CN104774172B (zh) * | 2015-04-08 | 2017-03-22 | 河南师范大学 | 一种3‑氰基吲哚类化合物的合成方法 |
| CN106478500B (zh) * | 2015-09-02 | 2020-02-11 | 广东东阳光药业有限公司 | 羧酸取代的(杂)芳环类衍生物及其制备方法和用途 |
| CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
| WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| WO2018157801A1 (zh) * | 2017-02-28 | 2018-09-07 | 广东东阳光药业有限公司 | 氰基取代的稠合双环衍生物及其制备方法和用途 |
| JP7763589B2 (ja) | 2018-05-18 | 2025-11-04 | バイオベラティブ セラピューティクス インコーポレイテッド | 血友病aを処置する方法 |
| EP3805210B1 (en) | 2018-06-01 | 2023-11-29 | Autophagysciences, Inc | Novel compound and pharmaceutical composition comprising same |
| CN111072647B (zh) * | 2019-12-11 | 2021-02-26 | 沈阳药科大学 | 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途 |
| CN111072634B (zh) * | 2020-01-03 | 2022-07-22 | 中国医科大学 | 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用 |
| WO2022098057A1 (ko) * | 2020-11-04 | 2022-05-12 | 주식회사 엘지화학 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정성 입자의 제조방법 및 이를 포함하는 약학적 조성물 |
| WO2022119269A1 (ko) * | 2020-12-01 | 2022-06-09 | 주식회사 엘지화학 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제 |
| CN116528853B (zh) * | 2020-12-01 | 2026-03-20 | 信达生物科技有限公司 | 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的口服制剂及其制备方法 |
| CN112920170B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | N-(吲哚-5-基)芳香杂环酰胺类化合物及其制备方法和用途 |
| KR102585644B1 (ko) * | 2021-04-16 | 2023-10-06 | 주식회사 엘지화학 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 경구용 제제 |
| WO2022231263A1 (ko) * | 2021-04-27 | 2022-11-03 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
| CN117242062A (zh) * | 2021-04-27 | 2023-12-15 | 株式会社Lg化学 | 用于合成黄嘌呤氧化酶抑制剂的中间体的制备方法 |
| US20240239768A1 (en) * | 2021-04-27 | 2024-07-18 | Lg Chem, Ltd. | Method for preparing xanthine oxidase inhibitor |
| EP4335844A4 (en) * | 2021-05-07 | 2025-08-27 | Jiangsu Atom Bioscience And Pharmaceutical Co Ltd | CLASS OF XANTHINE OXIDASE INHIBITORS |
| CN117412746A (zh) | 2021-06-15 | 2024-01-16 | 株式会社Lg化学 | 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的药物组合物 |
| AR126164A1 (es) * | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
| TWI822151B (zh) * | 2021-07-02 | 2023-11-11 | 南韓商Lg化學股份有限公司 | 製備黃嘌呤氧化酶抑制劑的方法 |
| EP4349809A4 (en) | 2021-07-02 | 2024-10-09 | Lg Chem, Ltd. | METHOD FOR THE PREPARATION OF AN INTERMEDIATE FOR THE SYNTHESIS OF A XANTHINE OXIDASE INHIBITOR |
| JP7792730B2 (ja) * | 2022-04-27 | 2025-12-26 | 杭州新元素▲薬▼▲業▼有限公司 | 尿酸を降下させるために使用できる化合物 |
| WO2023208103A1 (zh) | 2022-04-27 | 2023-11-02 | 江苏新元素医药科技有限公司 | 可用于痛风的化合物 |
| CN116283946B (zh) * | 2023-03-27 | 2024-05-07 | 武汉工程大学 | 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用 |
| TW202509022A (zh) | 2023-07-10 | 2025-03-01 | 南韓商Lg化學股份有限公司 | 製備用於合成黃嘌呤氧化酶抑制劑之中間體之方法 |
| CN118598859B (zh) * | 2024-05-21 | 2025-08-19 | 武汉工程大学 | 一种含氮杂环吲哚类黄嘌呤氧化酶抑制剂及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011131A2 (en) * | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
| WO2008126898A1 (ja) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | (アザ)インドール誘導体及びその医薬用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122008000051I1 (de) | 1990-11-30 | 2009-02-05 | Teijin Ltd | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel |
| ID21775A (id) | 1996-10-25 | 1999-07-22 | Yoshitomi Pharmaceutical | Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya |
| US6635640B2 (en) * | 2000-06-30 | 2003-10-21 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| ES2250422T3 (es) * | 2000-07-10 | 2006-04-16 | Bristol-Myers Squibb Company | Composicion y actividad antiviral de derivados de piperazina indoloxoaceticos sustituidos. |
| DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
| AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
| KR20080035594A (ko) * | 2005-07-01 | 2008-04-23 | 닛뽕 케미파 가부시키가이샤 | 크산틴옥시다아제 저해제 |
| US7816558B2 (en) * | 2005-10-07 | 2010-10-19 | Astellas Pharma Inc. | Triarylcarboxylic acid derivative |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| JP2008179621A (ja) * | 2006-12-28 | 2008-08-07 | Taisho Pharmaceutical Co Ltd | 含窒素飽和複素環化合物 |
| WO2008126770A1 (ja) | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体の製造方法 |
| EP2133331A4 (en) | 2007-04-11 | 2011-06-22 | Kissei Pharmaceutical | FIVE-GLASS HETEROCYCLIC DERIVATIVE AND ITS USE IN MEDICAL PURPOSES |
| JP5587784B2 (ja) | 2008-10-15 | 2014-09-10 | キッセイ薬品工業株式会社 | 縮合複素環誘導体及びその医薬用途 |
| AU2009303519B2 (en) | 2008-10-16 | 2014-09-25 | Automatic Bar Controls, Inc. | Apparatus and method and turntable for on-demand distributing of a food product |
| JP5529876B2 (ja) * | 2008-10-17 | 2014-06-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mmp−13阻害剤として有用なヘテロアリール置換インドール化合物 |
| KR20120068947A (ko) * | 2009-09-24 | 2012-06-27 | 에프. 호프만-라 로슈 아게 | Crac 조절제로서의 인돌 유도체 |
-
2010
- 2010-10-01 TW TW099133473A patent/TWI423962B/zh active
- 2010-10-04 CN CN201080044868.1A patent/CN102574839B/zh active Active
- 2010-10-04 EP EP10822213.4A patent/EP2467378B1/en active Active
- 2010-10-04 KR KR1020100096578A patent/KR101751325B1/ko active Active
- 2010-10-04 MX MX2012003782A patent/MX2012003782A/es active IP Right Grant
- 2010-10-04 WO PCT/KR2010/006760 patent/WO2011043568A2/en not_active Ceased
- 2010-10-04 MA MA34731A patent/MA33880B1/fr unknown
- 2010-10-04 JP JP2012533074A patent/JP5702392B2/ja active Active
- 2010-10-04 ES ES10822213.4T patent/ES2599829T3/es active Active
- 2010-10-04 US US13/498,253 patent/US8729273B2/en active Active
- 2010-10-04 AU AU2010304091A patent/AU2010304091B2/en active Active
- 2010-10-04 AP AP2012006191A patent/AP3346A/xx active
- 2010-10-04 BR BR112012007828A patent/BR112012007828B8/pt active IP Right Grant
- 2010-10-04 EA EA201270520A patent/EA021025B1/ru unknown
- 2010-10-04 UA UAA201204342A patent/UA110197C2/ru unknown
- 2010-10-04 MY MYPI2012700104A patent/MY162813A/en unknown
- 2010-10-04 TR TR2012/03989T patent/TR201203989T1/xx unknown
- 2010-10-04 CA CA2774133A patent/CA2774133C/en active Active
- 2010-10-04 SG SG2012018768A patent/SG179186A1/en unknown
- 2010-10-04 PE PE2012000438A patent/PE20121088A1/es active IP Right Grant
- 2010-10-05 AR ARP100103609A patent/AR078504A1/es active IP Right Grant
-
2012
- 2012-03-15 IL IL218669A patent/IL218669A/en active IP Right Grant
- 2012-03-23 EC ECSP12011793 patent/ECSP12011793A/es unknown
- 2012-03-23 CO CO12049241A patent/CO6430501A2/es active IP Right Grant
- 2012-03-23 CL CL2012000738A patent/CL2012000738A1/es unknown
- 2012-04-10 ZA ZA2012/02544A patent/ZA201202544B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011131A2 (en) * | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
| WO2008126898A1 (ja) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | (アザ)インドール誘導体及びその医薬用途 |
Non-Patent Citations (1)
| Title |
|---|
| KELVIN BILLINGSLEY ET AL: "Highly Efficient Monophosphine-Based Catalyst for the Palladium-Catalyzed Suzuki-Miyaura Reaction of Heteroaryl Halides and Heteroaryl Boronic Acids and Esters", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, no. 11, 1 March 2007 (2007-03-01), pages 3358 - 3366, XP055056735 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3346A (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
| HUS1700051I1 (hu) | Pirrolopiridin vegyületek, mint CDK inhibitorok | |
| ZA201608799B (en) | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
| ZA201208198B (en) | Picolinamide and pyrimidine-4-carboxamine compounds, process for preparing and pharmaceutical composition comprising the same | |
| WO2010093191A3 (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
| ZA201209297B (en) | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) | |
| IL207099A0 (en) | 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-??-secretase (bace) | |
| ZA201203183B (en) | Sulfomethylsuccinates, process for making same and compositions containing same | |
| IL211018A (en) | Inhibitors, processes for making them, medicinal preparations containing them and their use | |
| MY144726A (en) | Diosmetin compounds, process for their preparation and pharmaceutical compositions containing them | |
| ZA201108292B (en) | New compounds,pharmaceutical composition and methods relating thereto | |
| EP2439198A4 (en) | NOVEL PROCESS FOR PREPARING ROSUVASTATIN, INTERMEDIATE COMPOUNDS USEFUL FOR PREPARING ROSUVASTATIN, AND CORRESPONDING PREPARATION METHOD | |
| ZA201103444B (en) | Heteroaromatic compounds for use as hif inhibitors | |
| IL207183A (en) | Dihydroindolone compounds, a process for their preparation and their pharmaceutical compositions | |
| GB0800570D0 (en) | Composition, process for preparation and method of use | |
| IL203064B (en) | A pharmaceutical preparation containing compound 11 - deoxy - prostaglandin and a method for stabilizing the compound | |
| AP2011005885A0 (en) | Flavanoid compounds and process for preparation thereof. | |
| IL212850A0 (en) | Novel method for the preparation of granulates of active constituents, and granulates as obtained | |
| AP2012006352A0 (en) | AzabicycloÄ3.1.0Ühex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same. | |
| IL210049A0 (en) | Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it | |
| SI2332910T1 (sl) | Novi derivati azabiciklo(3.2.0)hept-3-ila, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo | |
| HK1171733A (en) | Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid | |
| EP2289989A4 (en) | ADDITIVE, MANUFACTURING METHOD THEREOF, AND COMPOSITION CONTAINING SAME | |
| HK1162499A (en) | Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1 |